Latest Cost Management News

Fortescue Metals Group delivered record iron ore shipments in FY25 alongside a rare cost decline, while recalibrating its green energy ambitions and maintaining a strong financial position.

ReadCloud Limited reported a robust 35% increase in cash receipts for the June quarter, driven by strong growth in its VET-in-Schools segment and disciplined cost management. The company forecasts positive underlying EBITDA and operating cash flow for FY25, positioning itself for accelerated growth in 2026.

Highfield Resources has entered a significant non-binding agreement with China’s Qinghai Salt Lake Industry for a US$300 million equity injection, aiming to fast-track its Muga potash mine development and expand its global footprint.

Bod Science reports a solid net cash inflow of $858,000 in Q4 FY2025, driven by R&D incentives and Biortica funding, while awaiting shareholder approval to complete a key acquisition.

InhaleRx Limited has secured key ethics approvals and initiated manufacturing for its inhaled drug candidates targeting breakthrough cancer pain and panic disorder, supported by a $38.5 million funding facility to accelerate development.

Credit Clear Limited has outperformed its FY25 financial guidance with a 76% rise in underlying EBITDA and secured exclusive digital debt recovery contracts with leading insurers, setting a robust stage for FY26 growth.

Perpetual Limited reported a 2.5% increase in assets under management to A$226.8 billion for Q4 FY25, driven by strong market performance and inflows. The company reaffirmed its expense guidance and continues to pursue the sale of its Wealth Management business.

OMG Group Limited has reported a remarkable 253% increase in quarterly cash receipts for Q4 FY25, driving annual revenues up 63% to $4.13 million and positioning the company for further growth in FY26.

Noble Helium appoints Dennis Donald as Executive Chairman and secures a $200k loan to accelerate its North Rukwa helium project, backed by positive technical reviews.

South32 has exceeded its FY25 production targets, driven by a 20% increase in copper output and significant progress at its Hermosa project, while streamlining its portfolio through key divestments.

Contact Energy's June 2025 report reveals stable mass market electricity and gas sales with improved netback prices, alongside rising wholesale revenues and ongoing renewable energy investments.

Mesoblast has reported a strong commercial debut for Ryoncil, the first FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft-versus-host disease, generating US$13.2 million in gross revenue in its initial quarter. The company is advancing regulatory and clinical milestones while expanding insurance coverage across the US.